Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Rises By 90.3%

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 27,111 shares, an increase of 90.3% from the August 15th total of 14,245 shares. Based on an average daily volume of 331,733 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Chugai Pharmaceutical Stock Down 1.2%

Shares of OTCMKTS CHGCY opened at $20.54 on Thursday. The business’s 50 day moving average is $21.74 and its two-hundred day moving average is $24.49. Chugai Pharmaceutical has a 52-week low of $20.00 and a 52-week high of $34.84. The firm has a market cap of $67.61 billion, a price-to-earnings ratio of 22.33 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Analysts anticipate that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

CHGCY has been the subject of a number of recent analyst reports. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Finally, Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.